Depreotide Scanning in Sarcoidosis: Materials and Methods

We hypothesized that, because of the presence of somatostatin receptors on sarcoid granulomas, 99mTc-DP findings would frequently be positive in patients with sarcoidosis. We also speculated that 99mTc-DP would identify sites of extrapulmonary sarcoidosis. Moreover, there are no systematic data to help determine whether management trials utilizing 9 mTc-DP should be performed in sarcoidosis patients. Therefore, we conducted a prospective prevalence trial of 99mTc-DP scanning in sarcoidosis.

The study population comprised a convenience sample of patients with sarcoidosis who were seen at our institution between January and June 2002. The original diagnosis of sarcoidosis was based on the histologic demonstration of non-necrotizing granulomas with special stains that failed to reveal either fungal or mycobacterial organisms. Patients in whom sarcoidosis was diagnosed, based only on their clinical presentation (ie, without biopsy evidence of non-necrotizing granulomas), and those who were Evaluation
All subjects underwent a standard evaluation, which included a history and physical examination, a CXR, and pulmonary function tests (PFTs) with the measurement of the single-breath diffusing capacity of the lung for carbon monoxide (Dlco). Radiographic stage was defined by the CXR performed when the patient initially had received a diagnosis of sarcoidosis and followed the approach of Scadding, as follows: stage 0, normal CXR; stage I, bilateral hilar lymphadenopathy alone; stage II, bilateral hilar lymphadenopathy with interstitial infiltrates; and stage III, interstitial infiltrates alone.

This entry was posted in Sarcoidosis and tagged depreotide, gallium, nuclear imaging, sarcoidosis, somatostatin, stage.